Navigation Links
EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center
Date:4/2/2008

RICHMOND, Virginia and ROSH HAAYIN, Israel, April 2 /PRNewswire/ -- The Virginia Biosciences Commercialization Center (VBCC) recently announced the newest company to establish their U.S. office at the Virginia BioTechnology Research Park as a member of the VBCC program, EnzySurge, an Israeli bioscience company focused on chronic wound management.

"EnzySurge has developed DermaStream(TM) based on its proprietary Continuous Streaming Therapy(TM) (CST) technology. DermaStream(TM) is a comprehensive yet versatile treatment for hard-to-heal chronic wounds throughout the debridement, regeneration and closure phases, designed for hospitals, clinics and home treatment" stated Donna Edmonds, executive director of the VBCC. "We're very excited to support the introduction of this innovative product line to the U.S. market. "Pressure, venous and diabetic wounds are an increasing problem in the United States, with more than 6 million cases reported annually. Each year, more than 2.3 million Americans are treated for diabetes-related skin ulcers and more than 100,000 amputations are performed on diabetic patients due to non-healing wounds."

Treatment of chronic wounds is a costly, long, multi-step process that often requires hospitalization, and is extremely uncomfortable for the patient. The process involves debriding the wound, surgically removing unhealthy tissue, flushing the wound with anti-microbial products and keeping the open wound clear of infection to promote tissue regeneration and hopefully lead to wound closure.

The DermaStream device continuously streams fresh highly active solutions in an isolated, optimally receptive and bacteria-controlled wound environment, thereby provides faster, more effective and comprehensive chronic wound treatment - from wound debridement, through regeneration to closure

"We're dedicated to developing innovative solutions that expedite wound healing and improve patients' quality of lives," stated Amir Shiner, CEO of EnzySurge. "The VBCC program brings us closer to getting a much needed medical tool in the hands of the clinicians who can use them."

About the Park

The Virginia BioTechnology Research Park is currently home to a unique mix of more than 55 public and private bioscience companies, research institutes affiliated with the VCU Medical Center and major state and national medical laboratories. These companies are housed in nine buildings totaling more than 1.1 million square feet of space, representing an employee base that exceeds 2,000. The VBDC is the Virginia BioTechnology Research Park's business assistance program located in its 27,000-square-foot incubator. Since opening in 1995, 63 companies have started in the Park's incubator facility; 31 of which have graduated into larger spaces in the Park or greater Richmond community. The Park's Commercialization Center has been created to take incubator graduates through commercialization to M&A or IPO, giving the Park's tenants full-scale business assistance. The Commercialization Center is now the home of eight companies from the Israeli life science community and continues to expand its resource base. It has created alliances with leading incubators in Israel. To date, the Park has graduated three companies that are now publicly traded.

About EnzySurge

EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge's patented and FDA cleared DermaStream(TM) - is an innovative wound care platform, which together with a set of advanced bio-active solutions, forms the basis for the new and unique wound treatment modality - Continuous Streaming Therapy(TM) (CST). Dermastream(TM) enables a new, controlled chronic wound environment that ensures a continuous fresh supply of therapeutic solutions to the wound. DermaStream(TM) is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound life cycle from debridement, through regeneration to wound closure. DermaStream(TM) was designed for use in hospitals, clinics and for home care.

EnzySurge is committed to the development and delivery of innovative solutions that improve the quality of life of chronic-wound patients, by shortening healing time and reducing treatment costs. For more information, visit http://www.dermastream.com

Contact

Nicky Colomb

Virginia BioTechnology Research Park

Phone: +1-804-828-6884

E-mail: ncolomb@vabiotech.com

Web site: http://www.vabiotech.com

Boaz Gruener

Director of Marketing and Business Development

Phone: +972-54-4563608

Email: boazg@enzysurge.com


'/>"/>
SOURCE The Virginia Biosciences Commercialization Center andEnzySurge Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
3. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
4. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
5. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
6. BioMarin to Present at the BioCentury NewsMakers Conference
7. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
8. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
9. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
10. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
11. Bioscience Group Warns Policymakers Against Complacency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):